

60,000 Doctors are Passing Drug Company Secrets to Investors

Elite investors all over the world are raking in huge profits based on confidential information emanating from a massive drug-secret underground.

Andrew Snyder, editor-in-chief of *Volume Spike Alert*, in an exclusive interview, explains how you could easily pad your investment portfolios with triple-digit gains – just by sitting safely on the sidelines and watching the notorious “**Drug Secret Money Mill**” in action.

Triple-Digit Guarantee! **We’ll give you a shot at a fast triple-digit winner in the next 90 days – or you owe us nothing!** (*details below*)

Dear Reader,

Would you like to lock in gains of **84.77%** in only **7 days**, **128.57%** in only **8 days**, or **147.79%** in only **16 days**?

Of course you would! We certainly would... and we did! And in this short letter I’ll show you exactly how we did it – just by following the trail left behind by the “Drug Secret Money Mill.”

It could be the simplest, easiest, most ingenious investment opportunity of the year for fast, triple-digit gains. But it clearly won’t be around forever.

U.S. Senator Grassley, (R- Iowa), wants to bring the “Drug Secret Money Mill” to a grinding halt. Indeed, he wants the estimated 60,000 plus blabber-mouth doctors in the ubiquitous drug secret underground to stop talking to investors – spilling the beans on which drug companies to buy, or sell, for quick and easy profits.

In fact, immediately after reading an investigative report published by *The Seattle Times*, exposing this massive insider-trading scandal, he fired off a letter to U.S. Attorney General Gonzales and the Chairman of the SEC, demanding they pull the plug on the lucrative “Drug Secret Money Mill.”

So there’s no time to sit on your hands with this one.

All you need to know about how to pile stunning gain upon stunning gain simply by observing the “Drug Secret Money Mill” in action – is right here in this letter...

How to Profit from the Biggest

Insider-Trading Scandal of the Decade

In an eye-opening article, *The Seattle Times* described, clearly and concisely, what's secretly transpiring – *still today, right now* – behind locked laboratory doors, and why select investors are continuing to profit handsomely, all thanks to the drug secret underground.

It was not their intent of course, but the two award-winning investigative reporters who wrote the article, Luke Timmerman and David Heath, also provide valuable insight into how Andrew Snyder can successfully leverage the effects of the “Drug Secret Money Mill” for the benefit of ***Volume Spike Alert*** subscribers.

- **147.79% on XSNX.OB.**
We recommended it at \$1.13... held it for only 16 days... exited at \$2.80
- **102.14% on NMTI**
We recommended it at \$10.75... held it for only 102 days... exited at \$21.73
- **84.77% on NVAX**
We recommended it at \$3.02... held it for only 7 days... exited at \$5.58
- **122% on RNAI**
We recommended it at \$1.83... held it for only 12 days... exited at \$4.07
- **96.59% on EGOV**
We recommended it at \$4.40... held it for only 82 days... exited at \$8.65
- **58.62% on APT**
We recommended it at \$1.45... held it for only 5 days... exited at \$2.30
- **213.41% on MWY**
We recommended it at \$4.10... held it for only 96 days... exited at \$12.85

So, if you're a player... a trader... who wishes to also travel the sure, the quick and the easy path to earning “BIG MONEY” trading stocks or options – read on...

Doctors Know Which Drug Companies to Buy

And it's the perfect example of the rich getting richer...

As revealed in *The Seattle Times* article... when Wall Street powerhouses, like Smith Barney, UBS, Wachovia Securities and others play the biotech and pharmaceutical sector... and they want to attract, and keep, the biggest high net worth players on the street... they don't take any chances with their buy and sell recommendations.

So they don't trust their investment advice to arcane investment theory, technical or fundamental analysis, or multivariate stock screening programs that can only produce at best a calculated guess.

Clinical Test Results Can Skyrocket a Stock's Share Price

*“A stock price can go from, say, \$3 to \$7 after a phase I trial, to \$10 after a phase II trial... and when a phase III trial shows that a drug is viable, and you can go to the FDA, **the company's stock could triple!**”*

– Merrill Goozner, Center for

Because when millions, if not billions of dollars of current and future business are at stake – these firms don't want to guess... and they definitely don't want to guess wrong.

Science in the Public Interest

Besides, there's no point in analyzing the balance sheet or income statement of a drug or biotech company when you're gunning for a quick killing – a double- or triple-digit profit.

All that matters are the test results on those miracle-promising drugs locked behind laboratory doors.

Those tests results alone will determine whether a drug company's stock will quickly soar like a rocket – or drop like a dead weight.

And who knows best which drugs will be the big winners, or losers, in the race to become the next multi-billion dollar blockbuster drug?

Ongoing and Widespread

“Until now, the selling of drug secrets has been hidden from securities regulators and the public, but biotech and Wall Street insiders said the practice is widespread.”
– *The Seattle Times*

The research doctors who test those drugs, of course.

So Wall Street firms will pay research doctors to leak confidential test results to them before those results are formally published, and the rest of the Street can learn about it.

And so far, it's been money well spent...

Doctors Leak Word of a Drug's Success... and Investors Pocket a FORTUNE!

For example...


Brokerage firm Fulcrum Global Partners invited some of their well-heeled clients to listen in on a conference call with two doctors involved in the testing of a new drug called “Thelin,” designed to treat pulmonary hypertension – a rare and potentially fatal disorder of the blood vessels in the lungs.

Earlier studies had raised concerns that Thelin, developed by Houston biotech company Encysive Pharmaceuticals, might cause serious bleeding, and could also damage the liver.

One of the doctors on the call, Harold Palevsky of the University of Pennsylvania, was on the drug's data safety monitoring board.

During the phone call, Dr. Palevsky told the listeners that the drug did not in fact produce any serious side effects, or at least none that would prevent it from being ultimately approved.

"The overall incidence of major bleeding events is rather low," said Dr. Palevsky.



Shortly after the conference call, Fulcrum Global Partners advised their clients to load up on shares of Encysive.

Five days later, Encysive indeed announced the study had succeeded. Patients on the drug had exhibited no serious bleeding episodes.

On that day, Encysive's stock surged on the busiest trading volume in its history.

Fulcrum's clients made a killing!

Unbelievable but True!

When doctors talk, investors make money.

But not *small investors*... just the big, deep pocket investors.

Personally, I don't think that's fair. And neither does Andrew Snyder, Editor-in-Chief of ***Volume Spike Alert***. So Andrew took it upon himself to level the playing field for the small and mid-sized investor.

And in a moment I'll show you exactly how he's doing it, and how you could easily and quickly rack up double- and triple-digit gains in only a few days.

It's Widespread and it's been going on for Years!

Until now, the selling of drug secrets has been hidden from securities regulators and the public, but biotech and Wall Street insiders say the practice is widespread and ongoing.

"Everybody does this.... It's now common practice," says Ben McGraw, a former Wall Street analyst and now CEO of California biotech company Valentis.

But that type of secret information doesn't come cheap.

Investors routinely pay up to \$1 million a year to firms known as "matchmakers" who go out and find doctors involved in ongoing drug research – and who are willing to talk.

The largest matchmaker is the Gerson Lehrman Group. They claim to have 60,000 doctors available to speak to Wall Street – double the number of three years ago!

So who else, other than Wall Street insiders, knew that all this leaking of information and insider trading was going on?

I didn't, and I bet you didn't – but Andrew Snyder knew.

Below is an edited copy of an actual email alert that was recently sent to ***Volume Spike Alert*** subscribers.

Listen to Your Doctor – He Could Make You Rich!

"With an estimated 10 percent of the nation's physicians now serving as consultants to the investment industry, the possibility of a slip of the tongue or of direct attempts at influencing the value of a stock has increased."

– ***Johns Hopkins Medicine***,
published by Johns Hopkins
University

“Insiders Snap Up Shares Worth \$6 MILLION in just 8 MINUTES!”

Volume Spike Alert # 269a

Folks, we're in great shape going into the weekend with **Sirna Therapeutics (RNAI: NASDAQ)**. Their insiders threw us a real softball today.

I picked up some unusual volume earlier this morning so I took a look at this chart:



This is what happened:

Earlier this week, RNAI announced its plans to issue over US\$28 million in a private placement of common stocks and warrants. The arrangement is for capital and venture investors to purchase RNAI shares at US\$1.60 per share.

Approximately 17 million shares of the company will be issued. So far, slightly over 8 million have been issued.

Once the deal is completed later this month, RNAI will use the influx of cash to continue developing major medical breakthroughs, especially its Signa-027 program.

The new capital will help the company quickly grow into a profit powerhouse.

But that was earlier this week. So what were insiders so happy about at 11:00 this morning?

Insiders bought nearly US\$6 million worth of RNAI shares in eight minutes. I don't doubt that the deal from earlier this week had some influence on today's shopping spree... But I think there's something else at work here.

After all, RNAI is an RNA (ribonucleic acid) interface drug manufacturer. They have a fair amount of drug candidates in the hopper going through trials and waiting for approval. The most recent of which will be studied by a Massachusetts hospital in hearing restoration studies.

There's a protein called retinoblastoma found in hearing loss victims. This protein damages the

inner ear hairs. RNAI has the potential to neutralize this protein and contribute to hair cell growth.

Some kind of news could be on the way. Obviously the insiders know something.

RNAI currently trades for \$1.82. I'd put a cap on buying this stock at around \$2.15 - \$2.20.

We went ahead and entered RNAI at \$1.83, held it for only 12 days, and then exited it at \$4.07 for a 122% gain.

Here's the chart:

Sirna Therapeutics (RNAI) Recommended: 07/08/05. Exited: 07/25/05.



This is just one example (more are below) showing you how Andrew can successfully follow the trail left behind by the “Drug Secret Money Mill” with stunning consistency.

And **Volume Spike Alert** subscribers love it.

These are just three glowing testimonials (more are below) out of 120 plus in Andrew’s so-called “Love Letters” file...

Understand that it’s not “science” that Andrew is practicing here. Nor is it some trumped up “secret system” either. And he’s certainly not reading tea leaves.

The best way to describe it is by saying... he has a highly refined talent – a gift that I’ve seen very few other analysts or successful traders possess... and believe me, I have known many.

Nevertheless, you need to act fast if you believe that **Volume Spike Alert** is your ticket to unheard of profits – because Senator Grassley is, in a word, **pissed!**

A 66% GAIN in Just One Day!

“My first trade with you guys -- love it. Bought 1500 shares ARGY at \$1.48 at 3:40 p.m. yesterday, out today at 10:30 at \$2.45 for a quick \$1,455 profit. Great call!! Thanks! Let's do it again and again and again!”

– T.D., **Volume Spike Alert** subscriber

A 325% GAIN!

“...On USGA, I was in at \$0.83 today and it's \$2.68. Wow an almost 325% gain. Keep them coming. Wish I subscribed 4 years ago. Best regards.”

– F.P., **Volume Spike Alert** subscriber

VSA Beats them All – Combined!

“I've made more money from your

U.S. Senator Grassley DEMANDS an Investigation

Based on the article in *The Seattle Times*, Senator Grassley, the powerful Chairman of the Senate's Finance Committee, fired off a letter to Attorney General Alberto Gonzales and the Chairman of the SEC, Christopher Cox, demanding an inquiry – and an immediate end to the selling of drug secrets to Wall Street.

Volume Spike Alert in the last 9 months than I have made from many other services combined, in the previous 5 years. Thank you and please keep the VSA's coming. Buying stocks is fun again."
– R.D ., **Volume Spike Alert** subscriber

Will the requested investigation lead to the shutting down of the “Drug Secret Money Mill” – the practice of selling insider information to investors so they can turn around and score huge profits trading drug and biotech stocks?

Most probably!

But, for right now... the SEC and the Justice Department haven't been able to seal the leaks... so Andrew Snyder is continuing to follow the trail of the “Drug Secret Money Mill” for all it's worth.

And he just found what could be the next great biotech play...

Here's Your Best Chance to Begin 2007 On Top of the Money Pile!

Andrew just discovered a biotech company that he believes could be benefiting from leaked insider information – possibly the results of clinical trials on a number of its cancer fighting drugs.

“There's been some highly suspicious volume activity occurring with this stock of late – particularly over the last few weeks,” said Andrew, in a recent phone interview.

And now he believes that this company's stock, currently priced at around \$7 a share, could *double, triple or quadruple* in value – for 400% gains in just the next few weeks!

Here's why...

A Small Seattle-Based Biotech Firm may have Developed the “SILVER BULLET” that Kills Cancer!!!

The company is primarily focused on producing biological drugs designed to attack cancer cells using “genetically engineered” monoclonal antibodies (MABs) and monoclonal antibody-drug conjugates (ADCs).

What are MABs and why should you care?

Real quickly, Antibodies are a type of white blood cell released by the body's immune system in response to the presence of a foreign entity, such as a virus, bacteria... or a cancer cell.

“...Many of the most innovative drugs being tested in labs world-wide are monoclonal antibodies.”
– **Wall Street Journal**

Monoclonal antibodies (MABs) are genetically engineered “clones” of these antibodies, and they will either block the growth of a cancer cell, or direct the body’s immune system to attack it.

“Monoclonal antibodies have been the great success story of biotechnology over the past decade. Since 1997 their worldwide sales have grown from zero to an estimated **\$14 Billion last year.**”
– *Financial Times*

Now, as you probably know, one of the most devastating drawbacks associated with most cancer therapies is “systemic toxicity” – the debilitating and painful side effects that accompany, for example, chemotherapy and radiation therapy.

The great benefit of MAB therapy, on the other hand, is that it’s “selective and specific.” In other words, MABs can literally bypass or ignore normal, healthy cells – dramatically reducing systemic toxicity.

However, clinical studies have found that most monoclonal antibodies on the market today are just not potent enough to kill cancer cells on their own.

That is... until now...

ADCs – Guided-Missiles Carrying a Toxic Warhead Inside Your Body

ADCs are monoclonal antibodies that are chemically linked (conjugated) to highly potent cell-killing (cytotoxic) drugs. Think of them as guided missiles with attached toxic warheads.

And these cell-killing warheads are engineered to release their explosive payload only within their designated targets – avoiding any harm or toxicity to surrounding healthy cells.

The key component of an ADC is the chemical “linker.” It’s the glue that attaches the drug to the monoclonal antibody until it’s “internalized” within the target cell where exposure to the intracellular environment results in the drug’s release.

Why this Company’s ADC Technology is the real MONEY-MAKER

The problem with ADCs to date is that the “linkers” have proven to be unstable, and the cytotoxic drugs that they’re linked to are either not powerful enough, or easily scalable (their potency is not easily adjusted).

Now to put that all in non-technical terms: You’ve got a warhead that doesn’t fit easily on top of a missile, might not explode on impact, or might just fall off the missile during flight.

This Seattle-based company, on the other hand, has developed patented and highly advanced ADC technology that utilizes extremely potent, proprietary drugs and revolutionary linkers that have been shown to be far more stable in the bloodstream than conventional linkers.

According to the ***Wall Street Journal***:

“...One of the company's pipeline ADC drugs had a positive

“For decades, medical researchers have dreamed of making these “silver bullets” into drugs.”
– *The Economist*

effect on lung-cancer patients in early trials, and shares have risen since the company unveiled the data at the American Society of Clinical Oncology.”

Is Big Pharma Looking to Buy this Company and their “Silver Bullets”?

Seven “big name” companies have already licensed the company’s ADC technology: Genentech, UCB Celltech, PDL BioPharma, CuraGen, Bayer Pharmaceuticals, MedImmune and PSMA Development Company (a joint venture between Progenics and Cytogen).

Licensing of their technology benefits this company in a number of obvious ways. But from the investor’s viewpoint it advertises – and proves – the company’s worth as a takeover target.

The \$2 Billion Molecule

As you know, biotech stocks have been on a tear recently – virtually burning up the charts as the biotech field quickly consolidates. And the payouts accruing from these mega-deals are making savvy investors very, very rich.

Bristol-Myers Squibb not too long ago agreed to pay **\$2 Billion** to gain marketing rights to a MAB developed by ImClone Systems. At the time it was the largest product deal ever between a big drug company and a small biotechnology firm.

Antibody developers are now in high demand as partnership or acquisition targets for big pharma looking to snap up the most promising pipelines and technologies – <i>Financial Times</i>
--

But not any more. That deal was just eclipsed. Amgen recently paid **\$2.2 Billion** to buy Abgenix, another company producing MABs.

Now AstraZeneca is negotiating to buy Cambridge Antibody Technology, in yet another sign that traditional pharmaceutical companies are intent on gobbling up small biotech companies.

And this news follows on the heels of Merck agreeing to pay a combined **\$480 Million** to buy two privately held biotechnology companies, GlycoFi of Lebanon, N.H., and Abmaxis of Santa Clara, CA.

And in the last few days biotech powerhouse Genentech, Inc. (NYSE: DNA) announced that it’s acquiring one of its smaller competitors, Tanox, Inc. (NASDAQ: TNOX), a biotech specializing in the discovery and development of biotherapeutics. The deal, worth **\$919 Million**, sent shares of Tanox **47% higher – in just one day!**

Why is Big Pharma Buying Up all the Biotech Companies?

Bigger profits, of course!

Pharmaceutical companies typically develop drugs made of chemicals, which can only be taken orally. Biotech companies develop drugs made of proteins, which are produced in living cells and must be injected.

Therefore, biologic drugs, because they're more difficult to produce and maintain, are fairly immune to competition from the generic drug companies that regularly eat up big Pharma's profits.

"Big Pharma has very few places to go to solve its problems, other than to pick up some of the big biotechs out there," said G. Steven Burrill of Burrill & Company, a biotech investment firm in San Francisco, and quoted in *The New York Times*.

But that's not the only reason this tiny, small-cap, \$280 million, biotech company that Andrew has been studying is such a tempting takeover target...

6 Big Reasons Why this Company is Such a Great Takeover Target

It doesn't own just one, or two MABs. It has a veritable arsenal of potential blockbuster biologic drugs locked-up in its vault – currently no less than six cancer treatments are in various stages of development and clinical trials – and more are on the way.

Right now it owns biologic drugs designed to attack cancers such as large cell lymphoma (ALCL), Hodgkin's disease, acute myeloid leukemia and multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, renal cancer, nasopharyngeal carcinoma, and a number of other hematologic malignancies.

Clearly, this company is sitting on a cancer-fighting gold mine!

On a conference call in October, the CEO of the company was accordingly asked, point blank, if the company was in "partnership" negotiations with a big pharma company.

His answer... a very telling, and diplomatic, "No comment."

Bill Gates Likes the Company So Much he's...

Buying it! His famous philanthropic organization, the Bill and Melinda Gates Foundation, recently bought more than 7% of all outstanding shares in the company.

And thanks to a buying streak that began this spring, Baker Brothers Investments, a family of investment funds for major university endowments and foundations, now have a stake worth over \$6 million in the company.

Important Note: Felix Baker and his brother, Julian, run Baker Brother Investments, a firm with many past successes in the biotech industry. It was one of the lead investors in **BioCryst (BRCX: NASDAQ)** in 2005. Shortly after the Bakers bought stock in that biotech company, its share price rose from around \$7 to more than \$20.

If this group of elite insiders is spending \$6 million to invest in this company, they must know

something... don't you think?

That's just one of the reasons why Andrew Snyder believes this stock could double, triple, quadruple or more in the next few weeks – making fast-acting investors rich, powerfully rich.

You can read more about this company in Andrew Snyder's **FREE** Special Report:

Understanding and Profiting from America's Multi-Billion Dollar "Drug Trade" Industry

So, are you intrigued... or scared?

Okay, let's answer right now the question that's probably burning foremost in your mind...

In fact, I'll let you read, in Andrew Snyder's own words, excerpted from an interview I conducted with him, exactly how he's able to uncover so many winners for **Volume Spike Alert** subscribers.

Why You can Buy Stocks or Options Based on a Volume Spike Alert Recommendation (without worrying about a late-night knock on your door)

ME: Andy, I'll ask you point-blank. Can a VSA subscriber be prosecuted for insider trading, and go to prison – like Martha Stewart – if they heed your buy and sell recommendations on select biotech stocks – or for that matter, any other stock or option – and scoring huge gains?

ANDY: (*Laughs*) Actually, you'd be amazed how many times I'm asked that question. First off, since when are triple-digit gains illegal? Secondly, Martha Stewart was not convicted of insider trading. She was charged with obstruction of justice, conspiracy, and securities fraud – not insider trading.

But to answer your question, no. Absolutely not.

ME: But you base your buy and sell recommendations on leaked insider information, don't you?

ANDY: Again – no. Absolutely not. I am not privy to insider information. I don't seek it out, nor will I listen to it, if it's ever presented to me. I don't break the law, and will not break the law, nor will I jeopardize my relationship with my VSA subscribers, or my publisher for that matter, by placing them in a compromising, untenable or illegal position vis-a-vis my buy or sell recommendations.

ME: Then why might some people think your remarkable gains on small, thinly covered stocks, be they in the drug sector or not, are due to material, non-public information?

ANDY: What people choose to believe about how I find my investment picks is beyond my control.

But ask me instead, *how* I find my recommendations – and I'll gladly answer that. It's no big secret.

Andrew Snyder Reveals the Secret to Racking Up Huge Gains with Small-Cap Stocks

ME: Fair enough. Andy, for the record, for all to read... what is the secret to your and VSA's success? How do you uncover the gems that you do, and ride them to huge gains in a relatively short period of time?

ANDY: Okay, here's the deal... the technical screens and charting software that I rely on are all calibrated to seek out and be super-sensitive to specific kinds of volume spikes – hence the name, ***Volume Spike Alert***. But, don't think for a moment that what I'm doing is setting an alert for a 5% or 10% volume spike on all the stocks on the New York Stock Exchange or the NASDAQ.

ME: Why not? How is it different?

ANDY: Well, first off you'd have to set a volume alert on more than 17,000 stocks – which is patently absurd. And then you would need at least a couple dozen filters just to weed out all the anomalies and “non-qualifiers.” And by the time you found the one or two that are worth researching it'll probably be some time next year!

And besides, most of the action, the big-profit plays, I'm looking for are in the super small-cap sector. These are stocks that no one follows – except for me, and maybe a few others. The average investor wouldn't even know where to look for these plays.

(*Scratching his head*) Look... this will be really difficult to explain, much less understand... but I'll tell you what...

Let me compare what I do... to playing golf.

ME: You're kidding...

“If You Can Swing a Golf Club You Can Earn Triple-Digit Gains Picking Stocks – Maybe...”

ANDY: Did you ever read the book, ***The Legend of Bagger Vance***?

ME: Loved it! Even non-golfers I know thought it was great – got a few of them to pick up a club.

ANDY: Okay, so here's the thing... when I look at a stock chart for example, I don't just see trend lines, volume, ratios and statistics...

Instead, I'm Bagger Vance, (*central character of the book*) standing on the 18th green on a small island off the coast of Savannah, Georgia in late summer.

Kneeling down, I survey the cut of the grass, how it lays, how the ground is sloping, how the wind is blowing, how low or high the sun is in the sky. I feel the grip, the weight of the putter in my hands

and how well it's balanced... and then... I remove myself from the physical reality of the green.

I close my eyes and put myself in a place of utter calm and confidence, and I let all the details fuse together to create a picture, a memory within me – where laying down a perfect putt and sinking the ball into that little cup – *or*, identifying a future buy or sell recommendation – is as natural and inevitable as a sunset at the end of a long summer day.

ME: Andy, c'mon... are you saying you “feel” when you have a triple-digit winning stock pick in front of you – as opposed to seeing it on a chart?

ANDY: Absolutely. Just as a golfer, or tennis player can feel he's made perfect contact with the ball when executing a perfect swing. I can feel a winning stock in my bones, in every fiber of my body and being.

ME: So... that's it? That's the whole process?

ANDY: (*Laughs*) No, of course not. That's just the beginning. Once I feel that telltale tingling sensation at the end of my fingertips as I'm punching keys on the computer keyboard – that's when I begin my investigative research to confirm my assumptions.

ME: Okay then... real quickly, tell the readers one of your “secret” indicators, if you will, that you look for in a stock that might eventually become either a buy or sell recommendation for *VSA* subscribers.

How to Tell When Insiders Could be... “Catapulting the Price of a Stock... Up or Down”

ANDY: No problem. Here's a classic example of what I consider to be a “contra-indicator” of an impending explosion, or implosion, in a stock's price...

If I see “suspicious” volume activity – clearly beyond the normal range – that's an obvious first indicator that something is up. That of course is a no-brainer.

But then... if I don't find any reason for that surge in volume in all the usual and obvious places – press releases, earnings reports, etc... then I go to my sources.

And by the way, in this business, if you don't have a Rolodex of well-connected names the size of two shoeboxes – you're dead in the water – you have no edge.

So then, if all my sources in that particular industry have no information – public information, I might add – that would cause the volume to spike on this particular stock – well then, that's when I get excited. *Really excited.*

ME: Why?

ANDY: Because it typically means that the stock is trading on insider information.

Someone is talking, someone influential who knows something material about the company or its products – and, someone is listening – and they, in turn, are talking to others and so on down the line.

And all these people are buying... or selling... shares of this stock based on that insider's information – and that's obviously what's spiking the volume.

So then... I've got to figure out what these insiders are saying – it's like reading a good mystery novel and trying to figure out who committed the crime before finishing the book.

Why? Because in my particular investment niche of fast and big gains – time is the enemy. There's just no time to sit, and ponder, and weigh – you've got to know, you've got to decide, and then you've got to execute – immediately.

So, the faster I can solve the murder (*Laughs*) the faster I can get a recommendation out to my subscribers.

Speaking of which, I'm putting the finishing touches on a special report on one such murder mystery – a biotech company in Seattle that I'm placing a buy recommendation on – which I'll be shooting out to my subscribers before the closing bell.

So, Chris...

ME: I hear you. Thanks for your time, Andy.

Golfing metaphors aside, there's obviously much more to Andy's stock picking "game" than finding the sweet spot on a golf club or tennis racquet...

Like the well-seasoned stock analyst and market commentator that he is, Andy relies a great deal on technical and fundamental research to flesh out his stock and option picks. And, as he mentioned, he's not above making a few well-placed phone calls to confirm his findings before a stock finally rises to the level of a VSA recommendation.

Andy also spends a great deal of time on the road, traveling throughout Europe, Canada and the U.S. sniffing out those hidden and hard-to-find profit opportunities.

And as soon as he uncovers a company he believes might be a "diamond in the rough," he has no qualms about picking up the phone and arranging a "face-to-face" with the company's CEO. And because his reputation inevitably precedes him, he's always welcomed into a company's inner sanctum.

Long Before YouTube.com and the Whole Web Video Craze Hit Wall Street, Andrew Predicted it All on Fox News

Research, in-depth research, is what drives Andy (even more than golf). He revels in the hunt – the challenge – of finding that one stock no one else is following – and everyone is missing – and riding its share price to triple-digit gains.

He's also tireless in his efforts to continually learn and excel as one the world's preeminent stock pickers.

Immediately after graduating from college, he became a licensed financial advisor. And then, partly for fun and partly to further his education, he helped launch a successful maritime shipping

business – so he could learn first hand how a quality company operates from the inside out.

Since then, he's become an award-winning author and regularly speaks at investor gatherings.

He was way ahead of Wall Street on the whole Web video craze. Last February, he was on *Fox News* talking about the gains that were on the way. And then of course, many of those gains were made – big time! Just look at what happened with YouTube.com!

The Taipan Group quickly spotted Andy as one of the premier up and coming stars in the stock picking arena and immediately offered him the editorship of one of its flagship trade advisory newsletters, ***The BreakAway Investor***.

And after quickly scoring impressive returns for investors there, I then personally asked him to also take the helm, as Editor-in-Chief, of The Taipan Group's ***Volume Spike Alert***.

And there's a boatload of ***Volume Spike Alert*** subscribers who are thrilled that I did...

86.6% in only 2 days!

“WOW!!! HOLY COW!!!! Great call. In at \$1.42 out at \$2.65 (86.6%) in 2 days! Just in time cause I'm going fishin' tomorrow and will not be by my computer the next couple of days. Thanks large.”
– R.K., VSA subscriber

\$85,000 in Profits!

“Sold NT for a \$45,000 profit and EGOV for a \$40,000 profit! Keep up the good work! My portfolio was up over 65% last year and up over 15% so far this year. You guys know how to pick them!”
– T.R., VSA subscriber

90% in Just One Hour!!

“Andrew, just sold my AQXXW puts for \$1.75 In 1 hour!! In at .85 out at 1.75. THANKS.
– T.S., VSA subscriber

Making Money the VSA Way – Is So Easy!

Here's why. When you become a ***Volume Spike Alert*** subscriber, as soon as Andy positively identifies a winning pick, he'll immediately send you a confidential ***VSA Alert***.

For example...

Novavax – A Biotech Company... “Capitalizing on the Avian Bird Flu Scare”

Volume Spike Alert # 6b

Here's a biotech company poised to see great gains from the avian bird flu scare. **Novavax (NVAX: NASDAQ)**. It specializes in the research, development, and commercialization of products for infectious diseases, and treating the avian flu is right up its alley.

Late yesterday, NVAX announced it teamed up with Wave Biotech to work on the commercial scale

production of NVAX's pandemic influenza virus (avian flu) vaccine.

This collaboration gives NVAX a big head start in the race to develop a vaccine before flu pandemic has the chance to develop.

Investors are keenly aware of the immense amount of money that is about to pour into this industry. Most are scrambling to find the company that is going to profit the most.

But without the right tools, the search is nearly impossible.

Fortunately, *Volume Spike* is on your side. I picked up on huge amounts of volume from NVAX today.

So far, over 22 million shares have traded hands, over seven times the average amount. With flu fears growing everyday, that volume is likely to continue to grow.

Shares of this company are ripe for the picking. **Buy all you can under US\$4.00.**

We recommended NVAX at \$3.02, held it for only 7 days then told our subscribers to exit it at \$5.58 for an 84.47% gain.

Not bad for just a week's work.

Here's the chart:

Novavax (NVAX) Recommended: 10/18/05. Exited: 10/25/05.



And Andy doesn't limit himself to just biotech plays. Check this one out...

XSunX – A Solar Energy Company “Doubling Your Money with Power Glass”

Volume Spike Alert # 23a

XsunX (XSNX.OB: OTC BB) has a product that will revolutionize the way the world uses solar energy. It's called Power Glass, a technology that has the ability to turn almost any translucent

surface, window glass for example, into an energy-efficient power producer.

No other company can boast of this accomplishment. In fact, XsunX holds three patents specific to this technology. Those patents ensure that this company will be a leader for decades to come in the US\$7 billion solar revolution.

Power Glass is such a huge innovation that it won the prestigious World Technology Award. A prize handed out to the greatest technological revolution of the year. Past winners have included Apple Computer, IBM, Sony, and Dow Chemical.

It's safe to say this award has propelled XsunX into the big leagues.

Worldwide electricity demand is expected to increase by more than 70% over the next 15 years. There is no way our current resources can supply that kind of demand.

I believe XsunX is the solution. Its Power Glass will allow the world to meet its energy demand while actually lowering dependence on non-renewable resources.

Instead of being huge black holes of power consumption, large buildings will be some of the greatest power generators.

Take a look at the Sears Tower in Chicago. This behemoth building has over 16,000 windows. If Power Glass was applied to the 644,000 square feet of translucent space those windows create, it would generate over 2 million watts of electricity. That is enough juice to power 11,709 55-inch TVs, or 9,541 computers, or 11,398 refrigerators.

Now, imagine if just half of the nation's tall buildings decide to install the Power Glass technology. The electrical savings would be astronomical and XsunX would be rolling in money.

XsunX's share price is going to soar.

The company's current market capitalization is just US\$169 million. And if my target price is reached, you'll soon be sitting on profits.

So here's what I want you to do. Invest just US\$2000 in XsunX, and set a stop loss at 10%. That way, the most you could lose is US\$200. But, if share price reaches my goal, you'll more than double your money.

Take a look at the chart. It's already started its move:



As I write this, shares of XsunX are selling for \$1.12. Buy under \$1.50.

We entered XSNX.OB at \$1.13, held it for only 16 days and then exited it at \$2.80 – for a stunning gain of 147.79%

Here's the chart:

XsunX (XSNX.OB) Recommended: 02/22/06. Exited: 03/17/06.



Here's our Triple-Digit Guarantee!

How confident am I that Andy could make you rich, fabulously rich?

This confident: I'll offer you a never-before-done **Risk-Free Guarantee**.

Try **Volume Spike Alert** for 90 days, and if at the end of only 90 days, we haven't given you the opportunity to score at least one triple-digit winner based on a **Volume Spike Alert** recommendation – just ask, and I'll personally see to it that you get your \$997 subscription fee back – immediately – if not sooner!

Still not convinced? Then take advantage of our “quarterly automatic renewal” option – for only **\$250 per quarter**. That is instead of paying for the annual service upfront, you'll receive 90 days of everything *Volume Spike Alert* has to offer for only \$250.

And just to be clear, I'll say that again. Give **Volume Spike Alert** a try for ninety days, and if in that time, we haven't recorded a triple-digit gain in our track record, giving you the opportunity for profits, then just let us know and we'll refund you 100% of your subscription fee... no questions asked.

3 Months of Andrew Snyder's Volume Spike Alert – FREE!

That's exactly what this unprecedented offer amounts to – if you're not satisfied. But how could you not be satisfied?

Look at some of the gains we've clocked:

- **133.33% on HDWR**, recommended at \$6.00... held it for only **60 days**... exited at \$14.00
- **128.57% on VISG**, recommended at \$3.50... held it for only **8 days**... exited at \$8.00
- **54.78% on ARTX**, recommended at \$1.57... held it for only **122 days**... exited at \$2.43
- **106% on PALM**, recommended at \$2.50... held it for only **44 days**... exited at \$5.15
- **85.33% on PHIC.OB**, recommended at \$.75... held it for only **276 days**... exited at \$1.39
- **94.44% on NT**, recommended at \$1.08... held it for only **26 days**... exited at \$2.10
- **137.96% on FNSR**, recommended at \$1.08... held it for only **219 days**... exited at \$2.57
- **108.33% on QQQ (Calls)**, recommended at \$.60... held it for only **6 days**... exited at \$1.25

Are you ready?

Click on the “Subscribe Now” button at the bottom of this page, and follow the simple instructions for a quick triple-digit gain in 90 days or less – **or your money back**.

And as soon as you do I'll also send you Andy's **FREE** Special Report on the company with a holster full of “Silver Bullets” designed to kill cancer.

Understanding and Profiting from America's Multi-Billion Dollar “Drug Trade” Industry

Remember: Right now this biotech company is trading for around \$7 – and Andy thinks it's going to be a sure triple-digit winner, at the very least. He firmly believes its share price can easily double to \$14, triple to \$21 – and then who's to say it can't rise to \$25 or \$35 a share.

Bill Gates obviously has confidence in it – he's been buying it! And there are probably a few big Pharma companies looking to snatch it up, too! Beat them to the punch. Lock in your gains now!

Plus, You'll Also Receive...

In addition to Andy's **Free** Special Report, you'll have ongoing and regular updates on the status of this biotech company. And when the time comes to sell it, Andy will tell you when to bank your gains.

Not only that, but anytime a new “*Volume Spike Alert*” occurs, you'll be instantly notified.

AND: You'll also receive all of the exclusive benefits and privileges that ***Volume Spike Alert*** offers, including:

- **Confidential *Volume Spike Alerts*:** When Andy spots an opportunity to make big gains, you'll be the first to know. You'll receive an e-mail from him telling you what's happening,

recommending what to buy, and at what price. And when it's time to sell, he'll let you know immediately. And then all you have to do is haul your profits to the bank. It's that simple!

- **FREE Daily Updates:** Every day, Andy will send you a market pulse update, detailing what's happening in the market – and giving you current info on all open positions.
- **FREE PRIVATE ACCESS to the VSA Members-Only Web site:** With investment updates, past and present alerts, and special investment articles.

Simply click the “Subscribe Now” link at the bottom of this letter to accept my special **Triple-Digit Guarantee**. Or call 1-877-465-1416, Monday-Friday, 9:00 a.m.-5:00 p.m. EST and we'll process your subscription request immediately.

Start 2007 in the money! Subscribe to **Volume Spike Alert** – it could be the smartest financial decision you'll make all year.

Sincerely,



Christian DeHaemer
Publisher, The Taipan Group

P.S. Our unprecedented “**Triple-Digit Guarantee!**” – **We pledge we'll give you a shot at a triple-digit winner in the next 90 days, or your money back!** – will not last forever. My accountants are pressing me to end this Risk Free Guarantee sooner rather than later (you know how nervous accountants are). And even though I keep telling them – there's nothing to worry about! **Andrew Snyder's Volume Spike Alert is a proven winner...** they insist I put a deadline on this offer... so before I do... take me up on our “**Triple-Digit Guarantee!**” **Subscribe Now!**

P.P.S. Late Breaking News: The cancer-fighting biotech company profiled in your FREE Special Report, **Understanding and Profiting from America's Multi-Billion Dollar “Drug Trade” Industry**, was again invited to make a presentation at the 48th annual conference for the American Society of Hematology (ASH).

And should the company reveal the results of their latest research and clinical trials, or announce a widely anticipated buyout offer...

Well, let me put it this way... last year, when the company presented at the ASH conference – its stock rose **64.48%** just in the brief time leading up to the conference.

P.P.S. Special Offer: Now you can sign up for our new “quarterly automatic renewal” option – for only \$250 per quarter.

[Subscribe Now](#)